The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
Owen A. O'Connor
Research Funding - TG Therapeutics
Changchun Deng
Research Funding - TG Therapeutics
Jennifer Effie Amengual
Research Funding - TG Therapeutics
Mazen Y. Khalil
Research Funding - TG Therapeutics
Marshall T. Schreeder
Research Funding - TG Therapeutics
Daruka Mahadevan
Research Funding - TG Therapeutics
Petros Nikolinakos
Research Funding - TG Therapeutics
Ahmed Sawas
Research Funding - TG Therapeutics
Jasmine M. Zain
Research Funding - TG Therapeutics
Molly Patterson
Research Funding - TG Therapeutics
Amber Moon
Research Funding - TG Therapeutics
Emily K. Pauli
Research Funding - TG Therapeutics
Kathy Cutter
Research Funding - TG Therapeutics
Michelle Ann Mackenzie
Research Funding - TG Therapeutics
Marnie Brotherton
Research Funding - TG Therapeutics
Jamie Hodgson
Research Funding - TG Therapeutics
Christen N Cooper
Research Funding - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Hari P. Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Charles Michael Farber
Honoraria - TG Therapeutics
Research Funding - TG Therapeutics